Drug intelligence / Profile preview

M40403 + opioid

Development stage
Preclinical
Lead developer
MetaPhore Pharmaceuticals
Modality
Small Molecules
Administration
Unknown (m40403: Administered Intraperitoneally In Animal Studies; Opioids: Oral, Intravenous, Intramuscular, Subcutaneous, Transdermal, Etc.)
01

Overview

M40403 + opioid refers to the combination of **M40403**, a synthetic manganese-containing superoxide dismutase (SOD) mimetic, with an **opioid analgesic**. M40403 selectively removes superoxide anion and has been investigated as an anti-inflammatory and potentially for pain management. Opioids are a class of analgesics that act as agonists at opioid receptors (mainly the mu opioid receptor), providing relief for moderate to severe pain. This combination is theoretical or investigational; there are no known marketed products or late-stage clinical trials specifically combining M40403 with an opioid. However, the concept fits with the ongoing research into multimodal analgesia, where opioid analgesics are paired with agents targeting oxidative stress or inflammation to provide synergistic pain control or reduce opioid requirements[3][7].

02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on M40403 + opioid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on M40403 + opioid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call